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Does mass drug administration of azithromycin reduce child 
mortality?
Child mortality remains prevalent in low-income 
and middle-income countries, with the sub-Saharan 
Africa region accounting for the largest under-5 
mortality rates.1 Although under-5 mortality rates have 
significantly decreased, most countries in sub-Saharan 
Africa with high mortality rates are unlikely to achieve 
the Sustainable Development Goal of at least as low as 
25 deaths per 1000 livebirths by 2030.2
Mass administration of azithromycin is one of the 
key interventions in trachoma control programmes 
and potentially reduces child mortality in sub-Saharan 
Africa.3,4 Several trials done in sub-Saharan Africa 
have reported mixed efficacy of mass administration 
of azithromycin in reducing child mortality at a 
population level.4 On the basis of this evidence, WHO, 
in 2020, recommended against the universal mass 
administration of azithromycin except for biannual 
administration for children aged 1–11 months in 
countries with high child mortality and where existing 
child survival interventions are also strengthened.3
In The Lancet Global Health, Patricia Pavlinac and 
colleagues5 did an individually randomised, double-
blind, placebo-controlled trial to assess the effect of a 
5-day course of azithromycin administered at hospital 
discharge on the risk of death and rehospitalisation 
in the subsequent 6-month period among children 
aged 1–59 months.5 In the study, eligible children 
from four hospitals in Kenya were randomly assigned 
to receive either azithromycin (oral suspension 
10 mg/kg on day 1, followed by 5mg/kg per day on 
days 2–5) or placebo, with the first dose being directly 
observed. Caregivers administered and recorded the 
subsequent doses and returned the bottles at the 
3-month follow-up. They also provided information 
on the child’s medical history during the 3-months 
and 6-months post-discharge follow-up visits, when 
whole stool or flocked rectal swabs were also collected 
to assess for azithromycin resistance in Escherichia coli 
isolates. Pavlinac and colleagues’ study is one of the 
few assessing the effects of mass administration of 
azithromycin in individual-level randomised trials. The 
authors found that, despite a high risk of mortality and 
readmission in the study population, azithromycin did 
not have beneficial effects on the combined outcome 
of readmission or mortality, with an incidence of death 
or rehospitalisation of 20·4 per 100 child-years in the 
azithromycin group versus 22·5 per 100 child-years 
in the placebo group (adjusted hazard ratio 0·91, 
95·5% CI 0·64–1·29, p=0·58), even after adjusting for 
medication adherence.5
The protective effect of mass administration of 
azithromycin has only been shown in population-wide 
cluster randomised trials, with no beneficial effect 
shown in one trial done in combination with seasonal 
malaria chemoprophylaxis,4 which could explain the 
difference in the findings. Additionally, most children in 
the study were treated with antibiotics during hospital 
admission and were discharged home with antibiotics, 
possibly affecting the potential effect of azithromycin. 
Regardless, this new evidence does not preclude the 
potentially beneficial effects of mass administration of 
azithromycin on child mortality or hospitalisation, as 
the study was not sufficiently powered to detect these 
effects independently and at the population level.
Similar to earlier studies showing that mass 
administration of azithromycin might propagate 
antimicrobial resistance,6 Pavlinac and colleagues found 
a concerningly high rate of azithromycin resistance in 
commensal Escherichia coli at baseline (37·7% in both 
study groups) and at 3 months post-randomisation, 
especially in the azithromycin group (26·9%) compared 
with the placebo group (19·1%; adjusted prevalence 
ratio 1·41, 95% CI 0·95–2·09, p=0·088).5 This was despite 
very low use of azithromycin during hospitalisation 
and study inclusion restricted to children at high risk of 
rehospitalisation and mortality. Concerns that mass drug 
administration will lead to the selection of macrolide-
resistant strains of endemic diseases and resistance to 
macrolides and other classes of antimicrobials in other 
pathogens are real barriers to further implementation. 
This reflects the growing evidence of increasing 
antimicrobial resistance among children7 and raises 
concerns because most countries in sub-Saharan Africa 
do not have robust antimicrobial surveillance systems.
As more research on the potential effects of 
azithromycin is done, phenotype-drug resistance profiles 
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for multiple organisms need to be integrated to provide 
robust evidence on antimicrobial resistance due to the 
mass administration of azithromycin.6 Importantly, 
the issues of community-wide azithromycin resistance 
should be of concern to policy makers and health 
practitioners, especially due to the recent use of 
azithromycin in some settings in sub-Saharan Africa for 
the management of COVID-19.8
It is increasingly clear that more research is needed 
to understand the specific mechanisms of action of 
azithromycin in reducing child mortality. Additionally, 
an assessment of the overall and age-specific effects 
of azithromycin on child mortality and morbidity 
in high quality, individually randomised, placebo 
controlled trials among children younger than 5 years 
is urgently needed to clarify the continued use of mass 
administration of azithromycin given the low level of 
evidence and risk for antibiotic resistance.
In general, child mortality is a complex public health 
issue, with multiple determinants that affect the health 
and wellbeing of children. Despite evidence that the mass 
administration of azithromycin effectively reduces child 
mortality at the population level for specific treatable 
endemic diseases such as trachoma,4 it is unlikely 
to be the magic pill that can independently reduce 
child mortality in sub-Saharan Africa. Downstream 
interventions to improve key determinants of health, 
including immunisation, nutrition, and access to clean 
and safe water, need to be strengthened to reduce the 
persistent disparities in child mortality across and within 
countries.
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